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Abstract  
 
Objectives 
To determine the diagnostic accuracy of surveillance mammography for detecting ipsilateral 
breast tumour recurrence and metachronous contralateral breast cancer in women previously 
treated for primary breast cancer. 
 
Methods 
A systematic review of surveillance mammography compared with ultrasound, magnetic 
resonance imaging (MRI), specialist-led clinical examination or unstructured primary care 
follow-up, using histopathological assessment for test positives and follow-up for test 
negatives as the reference standard.  
 
 
Results 
Nine studies met our inclusion criteria. Variations in study comparisons precluded meta-
analysis. For routine ipsilateral breast tumour detection, surveillance mammography 
sensitivity ranged from 64-67% and specificity ranged from 85-97%.  For MRI, sensitivity 
ranged from 86-100% and specificity was 93%.For non-routine ipsilateral breast tumour 
detection, sensitivity and specificity for surveillance mammography ranged from 50-83% and 
57-75% and for MRI 93-100% and 88-96%. For routine metachronous contralateral breast 
cancer detection, one study reported sensitivity of 67% and specificity of 50% for both 
surveillance mammography and MRI.   
 
Conclusion 
Although mammography is associated with high sensitivity and specificity, MRI is the most 
accurate test for detecting ipsilateral breast tumour recurrence and metachronous contralateral 
breast cancer in women previously treated for primary breast cancer. Results should be 
interpreted with caution because of the limited evidence base.   
 
Keywords 
‘Mammography’, ‘surveillance’, ‘diagnostic accuracy’, ‘neoplasm recurrence, local’, 
‘neoplasm, second primary’. 
 
Abbreviations 
MRI, magnetic resonance imaging; NIHR, National Institute for Health Research; HTA, 
Health Technology Assessment; CDSR, Cochrane Database of Systematic Reviews; DARE, 
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Database of Abstracts of Reviews of Effects; WHO, World Health Organisation; NCI, 
National Cancer Institute; NRR, National Research Register; QUADAS, quality assessment 
of diagnostic accuracy studies; LR, likelihood ratio; DOR, diagnostic odds ratio; IC, 
incalculable.  
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Introduction  
In women previously treated for breast cancer, surveillance mammography is useful for early 
detection of tumour recurrence, or for confirming the absence of recurrent cancer, and for the 
early detection of contralateral cancers. Although published figures vary, it has been estimated 
that approximately 50% of local recurrences in the breast following breast conservation surgery 
will be detected by mammography, with the remainder being detected by clinical examination 
or reported by the patient.[1-4]. Recurrent tumours detected by mammography are generally 
smaller and less invasive than those found on clinical examination[2, 4]. Lu and colleagues 
[5]  recently conducted a systematic review to determine the impact of early detection of 
isolated loco-regional and contralateral recurrence on survival.  The authors reported better 
overall survival for recurrences detected by mammography or in asymptomatic patients, with 
an absolute reduction in mortality of 17-28% if all breast cancer recurrences are detected 
early. 
 
While tumour recurrence displays similar mammographic features to the primary lesion [4],  
interpretation of the surveillance mammogram is made more difficult by surgical scarring and 
changes to breast density caused by primary treatment.  For example, following surgery and/or 
radiotherapy, detectable abnormalities on mammography may include the presence of old 
haematoma, scar formation, fat necrosis, skin thickening, increased soft tissue density in the 
breast and microcalcifications. Approximately 10% of palpable tumours are not clearly visible 
on mammography and require additional imaging techniques for their demonstration. 
Surveillance mammography is therefore also associated with the possibility of false-positive 
results, which then require further investigations that are unnecessary and have a negative 
impact on a woman’s quality of life.   
 
We conducted a National Institute for Health Research Health Technology Assessment 
programme funded project (NIHR HTA Project 07/47/01) to examine the clinical 
effectiveness and cost-effectiveness of different surveillance mammography regimens after 
the treatment of primary breast cancer in the UK in primary and secondary care settings.  The 
work comprised: a survey of UK breast surgeons and radiologists, a series of systematic 
reviews (diagnostic accuracy review presented here), and statistical and economic modelling 
to determine the effectiveness, cost consequences and cost utility of differing surveillance 
regimens. 
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The primary objective of this systematic review was to determine the test performance of 
surveillance mammography, alone or in combination with other tests, in detecting ipsilateral 
breast tumour recurrence and/or metachronous contralateral breast cancer in women 
undergoing routine surveillance.  Our secondary objective was to compare surveillance 
mammography performance with alternative tests, alone or in combination, in women with a 
previous diagnostic test result indicating suspected ipsilateral breast tumour recurrence and/or 
metachronous contralateral breast cancer (referred to subsequently as non-routine 
surveillance).   
 
Materials and methods  
We developed and followed a structured protocol.  We considered randomised controlled 
trials of surveillance mammography and diagnostic consecutive cohort studies of surveillance 
mammography or other comparator tests, involving women previously treated for primary 
breast cancer without detectable metastatic disease at the time of presentation for their initial 
treatment.  We also considered indirect (between-study) comparisons by comparing cohort 
studies analysing results of at least 100 women who received surveillance mammography, or 
a comparator test, or a combination of tests, with the reference standard test in the same 
population.   We excluded case reports and studies investigating technical aspects of a test.  
Comparator tests included ultrasound, magnetic resonance imaging (MRI), specialist-led 
clinical examination and unstructured primary care follow-up (defined as absence of formal 
routine secondary care follow-up, which may or may not involve mammography).  
The reference standard was histopathological assessment for test positives and a period of 
follow-up for test negatives.  
 
We chose to include studies assessing test performance for routine and non-routine 
surveillance patients. Adjunct tests are part of breast cancer surveillance management and the 
performance of diagnostic tests used for this purpose is relevant to our population of interest.  
The accuracy of non-routine adjunct imaging tests may differ from the accuracy of first-line 
surveillance tests as the test operator is primed to evaluate a suspicious finding in the 
non-routine surveillance patient.  It is unclear what effect this has on test accuracy but 
it is likely to focus attention on a particular area of the breast and may conceivably 
increase the diagnostic test sensitivity.  Consequently, we have not attempted to mix or 
compare the accuracy of tests used for these different purposes.  Similarly, because of 
anatomical differences between a “treated” and an “untreated” breast (due to 
treatment effects) it was inappropriate to combine data on test performance for the 
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detection of ipsilateral breast tumour recurrence and metachronous contralateral breast 
cancer. 
 
The following types of outcome were considered: 
• Test performance in diagnosing ipsilateral breast tumour recurrence in women 
undergoing routine surveillance 
• Test performance in diagnosing ipsilateral breast tumour recurrence in women 
undergoing non-routine surveillance 
• Test performance in diagnosing metachronous contralateral breast cancer in women 
undergoing routine surveillance  
• Test performance in diagnosing metachronous contralateral breast cancer in women 
undergoing non-routine surveillance  
 
To be considered for inclusion, the studies had to report the absolute numbers of true-
positives, false-positives, false-negatives and true-negatives, or provide information allowing 
their calculation, and report a per-patient analysis. 
 
In studies reporting the above outcomes, we planned to record the following additional 
outcomes, if stated: 
 
Adverse effects (defined as physical harms) of mammography and other tests 
• Acceptability of the tests 
• Reliability of the tests 
• Radiological/operator expertise (who conducts the test and previous experience) 
• Interpretability/readability of the tests 
 
Major electronic databases were searched using sensitive search strategies to identify 
diagnostic studies of surveillance mammography, MRI, ultrasound or clinical follow-up. 
Searches were conducted from 1990 to March 2009 and were restricted to the English 
language.  Conference abstracts were not included.  The following databases were searched 
for primary studies: Medline, Medline In process, Embase, Biosis, Science Citation Index, 
Cancerlit, while Medion, the Cochrane Database of Systematic Reviews (CDSR), Database of 
Reviews of Effects (DARE) and the HTA Database were searched for reports of evidence 
syntheses.  Reports of ongoing and recently completed trials were sought from Current 
Controlled Trials, Clinical Trials, WHO International Clinical Trials Registry Platform, NCI 
Clinical Trials Database, NRR Archive and NIHR Portfolio Database.  In addition, relevant 
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websites were searched and the reference lists of all included studies were scanned for 
additional reports. Full details of the search strategies used are available from the authors or 
the full study report, currently in press  (“The clinical effectiveness and cost-effectiveness 
of different surveillance mammography regimes after the treatment of primary breast 
cancer.” by Robertson et al accepted for publication in Health Technol Assess 2011). 
 From an initial first screening round of titles and abstracts we were able to exclude reports 
that were clearly irrelevant to the review (e.g. did not include any of our considered 
diagnostic tests).  We then assessed the full text versions of the remaining reports against our 
eligibility criteria using a screening tool comprising a checklist of our inclusion eligibility 
criteria, which we developed specifically for this review.  One reviewer independently carried 
out data extraction.  A second reviewer independently validated the data extraction.  We 
calculated sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds 
ratio for each included study.   
 
We evaluated the quality of studies using an adapted version of the Quality Assessment of 
Diagnostic Accuracy Studies QUADAS tool [6]. Higher quality studies were defined as those 
considering a representative patient spectrum and judged to have successfully avoided partial 
verification bias (whether the whole or random sample of the population received reference 
standard verification), differential verification bias (whether patients received the same 
reference standard) and test review bias (whether index and reference standard test results 
were interpreted independently).  Disagreement or uncertainty regarding data extraction or 
quality assessment was resolved by discussion or arbitration by a third reviewer.  
 
Results  
Figure 1 shows the flow of studies through the review.   
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2061 titles/abstracts screened (after 
exclusion of reports already identified by 
effectiveness review search) 
 
  1815 excluded 
237 reports excluded: 
Required participant eligibility not met: 77 
Index/comparator test(s) not assessed for 
ipsilateral breast tumour 
recurrence/metachronous contralateral 
breast cancer detection: 49 
Required reference standard not met: 6 
Required study design not met: 67 
Required outcomes not reported: 8 
Required comparator test not met: 19 
Retained for background information: 8 
Not available: 3 
9 reports included 
246 reports selected for full text 
assessment 
Figure 1: Flow of studies through the review process  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine studies met our inclusion criteria.  Variation across the included studies precluded 
formal meta-analysis.  We therefore present a narrative synthesis of the results.  Overall, the 
nine studies enrolled 4002 participants.  After exclusions, due to eligibility or 
participant drop-out, the studies included 3724 participants in their analyses.    The 
earliest study took place in 1995 [7] and the latest in 2009 [8]. The earliest participant 
enrolment date given was 1992 [7] and the latest was 2003 [8].  Four studies did not give any 
indication of the enrolment time period [9-12].  One study took place in Sweden [7], two in 
the UK [10, 11], two in Germany [12, 13],  two in South Korea [8, 14], one in Italy [9] and 
one in France [15].  Across studies the ages of the participants ranged from 22-82 years [8].  
Most participants were in their 50s.  The median age was 53 years (inter-quartile range 50 to 
56 years). Reported follow-up of test negatives ranged from 5 to 32 months. Table 1 provides 
details of the characteristics of the included studies. 
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Table 1  Summary of characteristics of the individual diagnostic accuracy studies 
Study ID Study Design Type of surveillance 
and primary surgery 
Index tests  Comparator test Follow-up time for verifying test negative 
results 
Belli 2002 [9] 
 
 
Direct head-to-
head cohort 
Non-routine 
surveillance breast 
conservation patients 
MRI for local recurrence 
  
Surveillance 
mammography, clinical 
examination, ultrasound 
for local recurrence 
 
MRI and clinical examination follow-up 
performed at 3 months. 
All MRI test negatives underwent cytological 
examination  
 
Boné 1995 [7] Direct head-to-
head cohort  
Routine surveillance 
mastectomy patients, 
all with breast 
reconstruction and 
implants 
 
Surveillance 
mammography for local 
and contralateral recurrence 
MRI, clinical 
examination for local and 
contralateral recurrence 
 
Median 10 months (range 5-18 months) 
Drew 
1998[10] 
 
Direct head-to-
head cohort 
Routine surveillance 
breast conservation 
patients 
MRI for local recurrence 
 
Surveillance 
mammography, clinical 
examination, surveillance 
mammography+clinical 
examination for local 
recurrence 
Median 341 days (range 168-451 days) 
Kim 2009[8] Direct head-to-
head cohort 
Routine surveillance 
breast conservation and 
mastectomy patients 
Adjunct ultrasound 
(surveillance 
mammography+ultrasound) 
for contralateral recurrence 
 
None 1-2 years 
Mumtaz 
1997[11] 
Direct head-to-
head cohort  
Non-routine 
surveillance breast 
Surveillance 
mammography for local 
MRI for local recurrence 
 
Median 12 months (range 6-15 months) 
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Study ID Study Design Type of surveillance 
and primary surgery 
Index tests  Comparator test Follow-up time for verifying test negative 
results 
conservation patients  recurrence 
  
Rieber 
1997[12] 
 
Cohort 
 
 
 
Non-routine 
surveillance breast 
conservation patients 
MRI for local recurrence  None clinical examination, ultrasound performed at 6 
months follow-up.  Surveillance mammography 
performed at 12 months’ follow-up.  In 22 patients 
a control MRI was performed at intervals of 2-16 
months (mean 7.2 months) 
Shin 2005[14] Cohort Routine surveillance 
patients (primary 
surgery type not 
reported) 
Ultrasound for local and 
contralateral recurrence 
 
None 6 months 
Ternier 
2006[15] 
Direct head-to-
head cohort 
Non-routine 
surveillance breast 
conservation patients 
Surveillance 
mammography for local 
recurrence 2 
 
Clinical examination, 
ultrasound for local 
recurrence 
6 months 
Viehweg 
2004[13] 
Direct head-to-
head cohort 
Routine surveillance 
breast conservation 
patients 
MRI for contralateral 
recurrence 
Conventional methods 
(surveillance 
mammography+clinical 
examination+ultrasound); 
MRI + Conventional 
methods for contralateral 
recurrence 
12 months 
Notes:  
1.  MRI, magnetic resonance imaging;  
2. Study authors considered computed tomography as the index test in this study but this test was not considered as an included comparator in this review
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Assessment of test performance  
Test performance in diagnosing ipsilateral breast tumour recurrence 
Table 2 shows test performance in detecting ipsilateral breast tumour recurrence in patients 
undergoing routine surveillance.  The studies by Boné and colleagues [7] and Drew and 
colleagues [10]  involved a total of 188 patients and reported the performance of surveillance 
mammography, MRI and clinical examination in routine surveillance patients.  These studies 
reported sensitivities of 64% and 67%, and specificities of 97% and 85%, respectively, for 
surveillance mammography.  For MRI, the studies reported sensitivities of 86% and 100% 
respectively, and for clinical examination 50% and 89%.  Boné and colleagues [7] did not 
report specificity for MRI or clinical examination.  The highest reported sensitivity was for 
MRI, and surveillance mammography combined with clinical examination (both 100%) while 
the highest specificity was for surveillance mammography (97%).  Similarly, a high 
specificity of 93% was reported for MRI.  The lowest reported sensitivity was for clinical 
examination (50%) and the lowest specificity was for surveillance mammography combined 
with clinical examination (67%). 
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Table 2  Sensitivity, specificity, likelihood and diagnostic odds ratios for detecting ipsilateral breast tumour recurrence in routine surveillance 
patients 
 
Notes: MRI, magnetic resonance imaging; LR+, Likelihood ratio of a positive test result; LR, Likelihood ratio of a negative test result; DOR, Diagnostic odds ratio; IC, 
Incalculable 
Test Study ID Primary surgical 
treatment 
Reported sensitivity 
% 
Reported specificity 
% 
LR+ LR- DOR  
(95% confidence interval) 
Surveillance 
mammography 
Boné 1995[7] 
Drew 
1998[10] 
Mastectomy 
Breast conservation 
64 
67 
97 
85 
22.2 
4.6 
0.4 
0.4 
60.3 (10.2-358.1) 
11.7 (2.6-52.4) 
MRI Boné 1995[7] 
Drew 
1998[10] 
Mastectomy 
Breast conservation 
86 
100 
Not reported 
93 
 
14.3 
 
IC 
 
IC 
Clinical examination Boné 1995[7] 
Drew 
1998[10] 
Mastectomy 
Breast conservation 
50 
89 
Not reported 
76 
 
3.7 
 
0.2 
 
25.4 (3.0-213.9) 
Combined surveillance 
mammography & 
clinical examination 
Drew 
1998[10] 
Breast conservation 100 67 3.0 IC IC 
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Table 3 shows test performance in detecting ipsilateral breast tumour recurrence in patients 
undergoing non-routine surveillance, as reported by Belli and colleagues [ 9], Mumtaz and 
colleagues[ 11], Rieber and colleagues [12], and Ternier and colleagues [15]. The studies 
involved a total of 156 patients.  Across these studies, for surveillance mammography the 
median (range) sensitivity was 71% (50% to 83%) and specificity was 63% (57% to 75%).  
For MRI, the studies by Belli and colleagues [9], Mumtaz and colleagues [11]  and Rieber and 
colleagues [12],  involving a total of 193 patients, reported sensitivity of  93% and 100% (two 
studies) and a median (range) specificity of 94% (88% to 96%).  Belli and colleagues [ 9] and 
Ternier and colleagues [15]  reported the test performance of ultrasound, with sensitivities of 
43% and 87%, and specificities of 31% and 73% respectively, and for clinical examination, 
sensitivities of 43% and 62%, and specificities of 56% and 49% respectively.  The highest 
reported sensitivity (100%) and specificity (96%) was for MRI.  The lowest reported 
sensitivities were (43%) for both ultrasound and clinical examination, while the lowest 
specificity was for ultrasound (31%).   
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Table 3  Sensitivity, specificity, likelihood ratio and diagnostic odds ratio for detecting ipsilateral breast tumour recurrence in non-routine 
surveillance patients  
Test Study ID Primary surgical 
treatment 
Reported 
sensitivity % 
Reported 
specificity % 
LR+ LR- DOR  
(95% confidence interval) 
Surveillance 
mammography 
Belli 2002[9] 
Mumtaz 1997[11]  
Ternier 2006[15]   
Breast conservation 
Breast conservation 
Breast conservation 
71 
50 
83 
63 
75 
57 
1.9 
2.0 
1.9 
0.5 
0. 7 
0.3 
4.2 (2.6 – 52.4) 
3 (0.6-14.0) 
6.3 (2.5-15.6) 
Ultrasound Belli 2002[9] 
Ternier 2006[15] 
Breast conservation 
Breast conservation 
43 
87 
31 
73 
0.6 
3.2 
1.8 
0.2 
0.3 (0.1-2.1) 
17 (6.2-46.5) 
MRI Belli 2002[9] 
Mumtaz 1997[11] 
Rieber 1997[12] 
Breast conservation 
Breast conservation 
Breast conservation 
100 
93 
100 
94 
88 
96 
16.0 
7.4 
24.2 
IC 
0.1 
IC 
IC 
91 (7.4-1126. 9) 
IC 
Clinical 
examination 
Belli 2002[9] 
Ternier 2006[15] 
Breast conservation 
Breast conservation 
43 
62 
56 
49 
1.0 
1.2 
1.0 
0.8 
1.0 (0.2-5.8) 
1.5 (0.7-3.4) 
Notes:  
1. MRI, magnetic resonance imaging; LR+,  Likelihood ratio of a positive test result; LR, Likelihood ratio of a negative test result; DOR, Diagnostic odds ratio; IC, Incalculable
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Test performance in diagnosing metachronous contralateral breast cancer 
Table 4 shows test performance in detecting metachronous contralateral breast cancer in 
routine surveillance patients.  The studies by Boné and colleagues [7] and Viehweg and 
colleagues [13]  involving a total of 202 patients, reported 67% and 91% sensitivity and 50% 
and 90% specificity, respectively, for MRI.  Only individual studies reported the test 
performance of surveillance mammography, clinical examination, and combinations of tests 
involving surveillance mammography.  The highest reported sensitivity (100%) was for 
combined surveillance mammography, clinical examination, ultrasound and MRI[ 13], while 
the highest reported specificity (99%) was for combined surveillance mammography and 
ultrasound [8]. The lowest reported sensitivity (0%) was for clinical examination and the 
lowest specificity was for surveillance mammography, MRI and clinical examination (all 
50%) [7].
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Table 4  Test performance as measured by sensitivity, specificity, likelihood ratio and diagnostic odds ratio for detecting metachronous 
contralateral breast cancer in routine surveillance patients 
Test Study ID Primary surgical 
treatment 
Reported  
Sensitivity 
% 
Reported  
Specificity 
% 
LR+ LR- DOR 
 (95% confidence 
interval) 
Surveillance mammography Boné 1995[7] Mastectomy 67 50 1.3 0.7 2.0 (0.1-78.2) 
MRI Boné 1995[7] Mastectomy 67 50 1.3 0.7 2.0 (0.1-78.2) 
 Viehweg 2004[13] Breast conservation 91 90 9.4 0.1 93.1 (11.0-786.2) 
Clinical examination Boné 1995[7] Mastectomy 0 50    
Combined surveillance 
mammography & ultrasound 
Kim 2009[8] Mastectomy  
Breast conservation 
95 99 61.5 0.05 1149.2 (148.0-
8937.8) 
Combined surveillance 
mammography, clinical examination 
& ultrasound 
Viehweg 2004[13] Breast conservation 64 84 3.9 0.4 8.9 (2.4-33.0) 
Combined surveillance 
mammography, clinical examination,  
ultrasound and MRI 
Viehweg 2004[13] Breast conservation 100 89 8.9 IC IC 
 
Notes: MRI, magnetic resonance imaging; LR+,  Likelihood ratio of a positive test result; LR Likelihood ratio of a negative test result; DOR, Diagnostic odds ratio; CI, 
Confidence interval; IC, Incalculable 
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None of the studies reported diagnostic accuracy of the included tests for diagnosing 
metachronous contralateral breast cancer in non-routine surveillance patients with a previous 
suspicious test result. 
 
Test performance in diagnosing ipsilateral breast tumour recurrence and metachronous 
contralateral breast cancer 
The study conducted by Shin and colleagues [14] was the sole study reporting overall test 
performance for diagnosing ipsilateral breast tumour recurrence and metachronous 
contralateral breast cancer.  Shin and colleagues evaluated ultrasound in routine surveillance 
patients, reporting a sensitivity of 71% and a specificity of 98%, LR+ 41.4, LR- 0.3, OR 
138.25 (95% CI 61.26 to 312.04). 
 
Quality assessment 
None of the studies met all of our criteria specified for higher quality studies, although in 
five[8, 9, 11, 12, 15] this was due to lack of clarity as to whether reference standard results 
were interpreted without knowledge of index test results only.  It was unclear in all but one 
study[14] whether the time interval between a positive test result and the histopathological 
reference standard was short enough to avoid improvement or progression of the condition 
occurring in the intervening period (disease progression bias).  We are therefore uncertain of 
the effects of this type of bias for positive test results in these studies.  All studies were judged 
to have appropriate follow-up time intervals for confirming negative test results and were 
therefore considered to be at low risk of disease progression bias for negative test results.  It 
was unclear in the study conducted by Shin and colleagues [14],  however, whether all 
patients with negative test results received follow-up and so there is a possible risk of partial 
verification bias for this study. 
 
Additional outcomes 
None of the included studies reported data concerning adverse effects, acceptability, 
reliability, radiological/operator expertise and interpretability/readability of the tests.  We 
found no discernible pattern for the histology of cancers detected and not detected both within 
and between diagnostic tests. 
Discussion  
Our findings should be interpreted with caution, as they are based on only nine studies 
involving a total of 3724 participants. Furthermore, the study conducted by Boné and 
colleagues [7]  included only mastectomy patients who underwent breast reconstruction using 
implants.  Surveillance of the chest wall and/or the reconstructed breast in patients receiving 
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either mastectomy alone, or mastectomy with breast reconstruction and implants, varies 
according to different health care systems and local protocols [16-18]. These comprise an 
increasingly relevant sub-group of women, because of increasing rates of breast 
reconstruction procedures, who might receive routine surveillance mammography in the 
future [19].  Results from this study should be treated as distinct from the others owing to the 
highly selected patient population who, whilst representing a subset of our considered 
population, differ greatly from the wider spectrum of women who receive surveillance in 
practice.  
Systematic reviews of diagnostic accuracy are highly complex and methodology in this area 
continues to evolve.  In terms of strengths, we believe that the methods adopted for this 
review are scientifically rigorous and compatible with current guidance in this area.  A 
limitation was that non-English language studies were excluded, potentially limiting the 
evidence base.  Of the studies included here, few evaluated the performance of the considered 
tests for similar purposes.  Furthermore, even where data were available it was not clinically 
appropriate to combine them, for example, because of differences between a “treated” and an 
“untreated” breast.  Similarly, it was inappropriate to combine data from routine and non-
routine surveillance patients.  Furthermore, no data were reported by the included studies on 
other aspects such as adverse effects or acceptability of the tests.   
 
Results for the index and comparator tests evaluated in this review were ascertained by 
subjective operator interpretation, either by visual inspection of an image of the breast 
(surveillance mammography, ultrasound and MRI) or by clinical examination of the breast.  
Data on the level of operator expertise or intra/inter-rater reliability were not reported.  It is 
therefore unclear whether these factors had any influence on reported test accuracy within, 
and between, studies and therefore whether any potential test operator bias exists.   
 
None of the studies met all of our criteria specified for higher quality studies, although they 
were judged to have reasonable internal validity.  All but one study [8] were considered to 
include a representative sample and therefore have good external validity.   
 
Conclusion  
Our findings suggest that MRI can be considered to have higher diagnostic value than 
surveillance mammography in women previously treated for primary breast cancer.  Of the 
test combinations reported, surveillance mammography combined with breast ultrasound 
could be considered the most accurate combination of tests for detecting metachronous 
contralateral breast cancer.  However these results should be interpreted with caution owing 
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to the paucity of data for all diagnostic tests available for breast cancer surveillance.  Further 
evidence on surveillance mammography and other diagnostic tests in this group of women is 
required in order to make a robust and informed judgement on their relative performance.  
Ideally a definitive randomised controlled trial should be undertaken focusing on those 
women at higher risk of ipsilateral breast tumour recurrence or metachronous contralateral 
breast cancer.  Such a trial might also compare more sophisticated surveillance regimens that 
vary not only in terms of the frequency of mammography or other diagnostic tests but also in 
terms of the frequency and setting of clinical follow-up.  Alternatively, high-quality, direct 
head-to-head studies could be undertaken comparing the diagnostic accuracy of tests used in 
the surveillance population.   
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